Phase III trial (EORTC 18071 / CA184-029) of post-operative adjuvant ipilimumab compared to placebo in patients with resected stage III cutaneous melanoma: Health Related Quality of Life (HRQoL) results

INTRODUCTION: HRQoL was a secondary endpoint in the EORTC 18071 phase 3 trial in stage III melanoma patients comparing adjuvant Ipilimumab at 10 mg/kg (Ipi, N=475) versus placebo (Pbo, N=476). The primary endpoint was recurrence-free survival [HR (95% CI) = 0.75 (0.64–0.90); P=0.0013]. Toxicity of I...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Lancet Oncol
Asıl Yazarlar: Coens, Corneel, Suciu, Stefan, Chiarion-Sileni, Vanna, Grob, Jean-Jacques, Dummer, Reinhard, Wolchok, Jedd D., Schmidt, Henrik, Hamid, Omid, Robert, Caroline, Ascierto, Paolo A., Richards, Jon M., Lebbe, Celeste, Ferraresi, Virginia, Smylie, Michael, Weber, Jeffrey S., Maio, Michele, Kotapati, Srividya, de Pril, Veerle, Testori, Alessandro, Eggermont, Alexander
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2017
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5636622/
https://ncbi.nlm.nih.gov/pubmed/28162999
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(17)30015-3
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller